Floatz logo

Tas-102

T-cell Large Granular Lymphocyte Leukemia

National Cancer Institute (NCI)unclassifiedPhase 2Dormant
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the T-cell Large Granular Lymphocyte Leukemia cohort.

Asset / SponsorPhaseRating
Fludarabine
Ohio State University Comprehensive Cancer Center
Phase 2BBB
Monomethyl Fumarate
University of Medicine and Dentistry of New Jersey
Phase 2BB
CYCLOSPORIN A
Case Comprehensive Cancer Center
Phase 2BB
Cyclophosphamide
Case Comprehensive Cancer Center
Phase 2BB
Busulphan
Ohio State University Comprehensive Cancer Center
Phase 2BB

View all 43 →

Same molecule, other indications

Tas-102 is also rated in:

Stage IV Renal Cell CancerDormant
BB
Indicative ·
68 / 100
View asset →
Stage IV Non-Small Cell Lung Cancer AJCC v7Dormant
BB
Indicative ·
68 / 100
View asset →
Carcinoma, Islet CellDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →